- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Future of Anti-Amyloid Trials ; volume:7 ; number:3 ; day:17 ; month:4 ; year:2020 ; pages:146-151 ; date:6.2020
The journal of prevention of Alzheimer's disease ; 7, Heft 3 (17.4.2020), 146-151, 6.2020
- Classification
-
Medizin, Gesundheit
- Creator
-
Aisen, P. S.
Cummings, J.
Doody, R.
Kramer, L.
Salloway, S.
Selkoe, D. J.
Sims, J.
Sperling, R. A.
Vellas, B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2020.24
- URN
-
urn:nbn:de:101:1-2020080222512588337359
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aisen, P. S.
- Cummings, J.
- Doody, R.
- Kramer, L.
- Salloway, S.
- Selkoe, D. J.
- Sims, J.
- Sperling, R. A.
- Vellas, B.
- SpringerLink (Online service)
Other Objects (12)
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein